Boston Scientific Corporation Website

Boston Scientific Corporation

NYSE-BSX

Basic

  • Market Cap

    $113.42B

  • EV

    $122.34B

  • Shares Out

    1,470.18M

  • Revenue

    $14.71B

  • Employees

    48,000

Margins

  • Gross

    69%

  • EBITDA

    25.44%

  • Operating

    17.18%

  • Pre-Tax

    14.6%

  • Net

    12.05%

  • FCF

    11.55%

Returns (5Yr Avg)

  • ROA

    5.52%

  • ROTA

    29.51%

  • ROE

    12%

  • ROCE

    7.05%

  • ROIC

    -1.31%

Valuation (TTM)

  • P/E

  • P/B

  • EV/Sales

  • EV/EBITDA

  • P/FCF

  • EV/Gross Profit

Valuation (NTM)

  • Price Target

    $82.26

  • P/E

  • PEG

  • EV/Sales

  • EV/EBITDA

  • P/FCF

Financial Health

  • Cash

    $2,329M

  • Net Debt

    $8,672M

  • Debt/Equity

    0.55

  • EBIT/Interest

    9.39

Growth (CAGR)

  • Rev 3Yr

    13.26%

  • Rev 5Yr

    8.16%

  • Rev 10Yr

    7.58%

  • Dil EPS 3Yr

    103.4%

  • Dil EPS 5Yr

    -1.45%

  • Dil EPS 10Yr

    15.86%

  • Rev Fwd 2Yr

    11.14%

  • EBITDA Fwd 2Yr

    13.38%

  • EPS Fwd 2Yr

    13.51%

  • EPS LT Growth Est

    11.71%

Dividends

  • Yield

  • Payout

  • DPS

  • DPS Growth 3Yr

  • DPS Growth 5Yr

  • DPS Growth 10Yr

  • DPS Growth Fwd 2Yr

Select a metric from the list below to chart it

Dec '14

Dec '15

Dec '16

Dec '17

Dec '18

Dec '19

Dec '20

Dec '21

Dec '22

Dec '23

LTM

Dec '24 (E)

Dec '25 (E)

Dec '26 (E)

Total Revenues

10,735

9,913

11,888

12,682

14,240

14,707

Total Revenues % Chg.

9.3%

-7.7%

19.9%

6.7%

12.3%

12.7%

Cost of Goods Sold, Total

3,103

3,242

3,760

4,003

4,391

4,559

Gross Profit

7,632

6,671

8,128

8,679

9,849

10,148

Selling General & Admin Expenses, Total

3,928

3,787

4,359

4,520

5,190

5,339

R&D Expenses

1,174

1,143

1,204

1,323

1,414

1,443

Amortization of Goodwill and Intangible Assets

699

789

741

803

828

839

Other Operating Expenses, Total

5,801

5,719

6,304

6,646

7,432

7,621

Operating Income

1,831

952

1,824

2,033

2,417

2,527

Interest Expense, Total

-473

-361

-341

-470

-265

-269

Interest And Investment Income

30

3

4

10

22

22

Net Interest Expenses

-443

-358

-337

-460

-243

-247

Currency Exchange Gains (Loss)

-35

-32

-27

-31

-41

-32

Other Non Operating Income (Expenses)

1

6

-7

-14

-16

-15

EBT, Excl. Unusual Items

1,354

568

1,453

1,528

2,117

2,233

Restructuring Charges

-83

-179

-40

-24

-69

-52

Merger & Related Restructuring Charges

-369

Impairment of Goodwill

-73

Gain (Loss) On Sale Of Investments

-30

383

250

-1

-59

-24

Gain (Loss) On Sale Of Assets

78

-22

Asset Writedown

-105

-452

-370

-132

-58

-58

Legal Settlements

-115

-278

-430

-173

111

111

Other Unusual Items

35

-49

136

-35

-58

-63

EBT, Incl. Unusual Items

687

-80

1,077

1,141

1,984

2,147

Income Tax Expense

-4,013

2

36

443

393

377

Earnings From Continuing Operations

4,700

-82

1,041

698

1,591

1,770

Minority Interest

1

2

Net Income

4,700

-82

1,041

698

1,592

1,772

Preferred Dividend and Other Adjustments

33

56

56

22

7

Net Income to Common Incl Extra Items

4,700

-115

985

642

1,570

1,765

Net Income to Common Excl. Extra Items

4,700

-115

985

642

1,570

1,765

Total Shares Outstanding

1,394.9

1,416.6

1,425.5

1,433.3

1,465.7

1,470

Weighted Avg. Shares Outstanding

1,391.5

1,416.7

1,422.3

1,430.5

1,453

1,461.2

Weighted Avg. Shares Outstanding Dil

1,410.6

1,416.7

1,433.8

1,439.7

1,463.5

1,472.4

EPS

3.4

-0.1

0.7

0.4

1.1

1.2

EPS Diluted

3.3

-0.1

0.7

0.4

1.1

1.2

EBITDA

2,842

2,075

2,917

3,169

3,613

3,742

Effective Tax Rate

-584.1%

-2.5%

3.3%

38.8%

19.8%

17.6%